Table 6.
Neonatal outcomes of pregnancies followed up from the first trimester by antimalarial treatment group
| No malaria, no treatment (13 470) | Chloroquine (262) | Quinine (260) | Artesunate (44) | p value | ||
|---|---|---|---|---|---|---|
| Stillbirths* | 153/13158 (1%) | 3/254 (1%) | 7/257 (3%) | 1/44 (2%) | 0·131 | |
| Male† | 6718/13 315 (50%) | 146/259 (56%) | 144/253 (57%) | 23/44 (52%) | 0·055 | |
| Congenital abnormality‡ | 198/13 339 (1%) | 1/260 (<1%) | 2/258 (1%) | 2/44 (4·5) | 0·117 | |
| Twins | 134/13 470 (1%) | 0 | 1/260 (<1%) | 1/44 (2%) | 0·225 | |
| Estimated gestational age at birth, weeks | 39·0 (1·8 [28·0–45·5]) | 38·8 (2·2 [28·0–44·0]) | 38·9 (2·1 [28·3–42·9]) | 38·9 (1·8 [32·6–41·4]) | 0·194 | |
| Birthweight not measured§ | 390/13 470 (3%) | 13/262 (5%) | 19/260 (7%) | 4/44 (9%) | <0·0001 | |
| Liveborn normal singleton infants§ | ||||||
| Birthweight measured <72 h | 11 204/12 204 (89%) | 192/239 (80%) | 171/233 (73%) | 29/38 (76%) | <0·0001 | |
| Birthweight, g | 2970 (451 [900–5080]) | 2917 (465 [790–4130]) | 2950 (488 [780–4300]) | 3035 (408 [2250–3900]) | 0·318 | |
Data are number (%) or mean (SD [range]).
*
Data missing for 312 patients in the no malaria, no treatment group, eight in the chloroquine group, and three in the quinine group.
†
Data missing for 155 patients in the no malaria, no treatment group, three in the chloroquine group, and seven in the quinine group.
‡
Data missing for 131 patients in no malaria, no treatment group, two in the chloroquine group, and two in the quinine group.
§
Weight measured and completed within 72 h of birth.